PEOPLE - Baxter International makes appointment:
This article was originally published in Clinica
Executive Summary
Baxter International has appointed Michel Canavaggio vice-president of its European research and development unit, effective June 1. He will be based in Nivelles, Belgium. Since 1999, Mr Canavaggio has been CEO of Genethon, a biotechnology center which develops gene therapy and cell therapy for the treatment of life threatening genetic diseases. He has previously worked with Abbott Laboratories.